EVIDENCE WATCH
A review and assessment of recent clinical trial data

Acute lymphoblastic leukemia
TOWARDS A PEDIATRIC APPROACH IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): THE GRAALL-2003 STUDY. ASH 2006, ABSTRACT 147.

Acute myeloid leukemia
GENE MUTATIONS AS PREDICTIVE MARKERS FOR POSTREMISSION THERAPY IN YOUNGER ADULTS WITH NORMAL KARYOTYPE AML. ASH 2006, ABSTRACT 4.

Multiple myeloma
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THALIDOMIDE PLUS DEXAMETHASONE VERSUS DEXAMETHASONE ALONE AS PRIMARY THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA. ASH 2006, ABSTRACT 795.

FIRST ANALYSIS OF THE AUSTRALASIAN LEUKAEMIA AND LYMPHOMA GROUP (ALLG) TRIAL OF THALIDOMIDE AND ALTERNATE DAY PREDNISOLONE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR PATIENTS WITH MULTIPLE MYELOMA. ASH 2006, ABSTRACT 58.

Adjuvant chemotherapy for early breast cancer
A RANDOMIZED TRIAL OF CEF VERSUS DOSE DENSE EC FOLLOWED BY PACLITAXEL VERSUS AC FOLLOWED BY PACLITAXEL IN WOMEN WITH NODE POSITIVE OR HIGH RISK NODE NEGATIVE BREAST CANCER, NCIC CTG MA.21: RESULTS OF AN INTERIM ANALYSIS. SABCS 2006, ABSTRACT 53.

Metastatic breast cancer
A RANDOMIZED PHASE 2 TRIAL OF QW OR Q3W ABI-007 (ABX) VS. Q3W SOLVENT-BASED DOCETAXEL (TXT) AS FIRST-LINE THERAPY IN METASTATIC BREAST CANCER (MBC). SABCS 2006, ABSTRACT 46.

Breast cancer epidemiology
A SHARP DECREASE IN BREAST CANCER INCIDENCE IN THE UNITED STATES IN 2003. SABCS 2006, ABSTRACT 5.

MATURE ANALYSIS FROM THE WOMEN’S INTERVENTION NUTRITION STUDY (WINS) EVALUATING DIETARY FAT REDUCTION AND BREAST CANCER OUTCOME. SABCS 2006, ABSTRACT 32.

Hormonal therapy for breast cancer
FULVESTRANT VERSUS EXEMESTANE FOLLOWING PRIOR NON-STEROIDAL AI THERAPY: FIRST RESULTS FROM EFECT, A RANDOMIZED, PHASE III TRIAL IN POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER.SABCS 2006, ABSTRACT 12.

Breast cancer prevention
LONG TERM EFFICACY OF TAMOXIFEN FOR CHEMOPREVENTION RESULTS OF THE IBIS-I STUDY. SABCS 2006, ABSTRACT 34.

20 YEAR FOLLOW-UP OF THE ROYAL MARSDEN TAMOXIFEN BREAST CANCER PREVENTION TRIAL. SABCS 2006, ABSTRACT 51.

Breast cancer in premenopausal women
THE IMPACT OF TREATMENT-INDUCED AMENORRHEA ON SURVIVAL OF PREMENOPAUSAL PATIENTS WITH ENDOCRINE-RESPONSIVE BREAST CANCER: 10-YEAR RESULTS OF ABCSG-05 (CMF VS. GOSERELIN+TAMOXIFEN). SABCS 2006, ABSTRACT 17.

Biological markers and chemotherapy in breast cancer
TOPOISOMERASE II ALPHA PROTEIN OVEREXPRESSION HAS PREDICTIVE UTILITY IN A RANDOMIZED TRIAL COMPARING CMF TO CEF IN PREMENOPAUSAL WOMEN WITH NODE POSITIVE BREAST CANCER (NCIC CTG MA.5). SABCS 2006, ABSTRACT 38.

A POOLED ANALYSIS ON THE INTERACTION BETWEEN HER-2 EXPRESSION AND RESPONSIVENESS OF BREAST CANCER TO ADJUVANT CHEMOTHERAPY. SABCS 2006, ABSTRACT 41.

Combined hormonal and targeted therapy
TRASTUZUMAB PROLONGS PROGRESSION-FREE SURVIVAL IN HORMONE-DEPENDENT AND HER2-POSITIVE METASTATIC BREAST CANCER. SABCS 2006, ABSTRACT 3.

Risk in T1a–bN0, HER2+ breast cancer
RECURRENCE RISK IN T1a-b, NODE NEGATIVE, HER2 POSITIVE BREAST CANCER. SABCS 2006, ABSTRACT 2037.

POOR 10 YR BREAST CANCER SPECIFIC SURVIVAL AND REPLAPSE FREE SURVIVAL FOR HER2 POSITIVE T1N0 TUMORS. SABCS 2006, ABSTRACT 2031.

Cancer stem cells and resistance to treatment
BREAST CANCER STEM CELLS ARE RESPONSIBLE FOR THERAPEUTIC RESISTANCE AND RESIDUAL DISEASE. SABCS 2006, ABSTRACT 205.

BREAST CANCER STEM CELLS AND TAMOXIFEN RESISTANCE . SABCS 2006, ABSTRACT 206.

STEM/PROGENITOR PHENOTYPES IN MCF-7 CELLS ARE ASSOCIATED WITH RADIATION RESISTANCE . SABCS 2006, ABSTRACT 207.